Intranasal Epinephrine

Advertisement

cGxPJobs Banner

Nasus Pharma Advances NS002 Toward Pivotal Anaphylaxis Study

TEL AVIV, Israel — September 14, 2026 Nasus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA)...

By cGxPwire Editor
September 16, 2026

Read More

Advertisement

cGxPJobs

Directory